

AMBULATORY TREATMENT UNIT

Vedolizumab (Entyvio) Infusion Order Set

□ = Optional Order • = Routine Order (Cross out and initial bulleted orders that do not apply.)

Phone (616) 394-3547 Fax (616) 394-2139

ORDERS	
Date: Time: Diagnosis Code: (ICD-10)	
Patient Name: Date of Birth:	Weight: (kg)
Allergies:	
TB Test Result: Date: *Initial TB Test required prior to first dose. optional, and to be ordered and evaluated by provider.	Any subsequent testing
MEDICATION ☐ Initial dose of vedolizumab (Entyvio) 300 mg IVPB, infuse over 30 minutes at 0, 2, and 6 weeks. ☐ Maintenance therapy of vedolizumab (Entyvio) 300 mg IVPB, infuse over 30 minutes every 8 weeks.	
 Vital signs to be completed prior to infusion, 15 min after start of infusion and at the completion of infusion. If patient is in the induction period of their infusions, patient should be monitored for 30 minutes post infusion including vital signs 30 minutes after completion of infusion. If the patient has no improvement of symptoms 14 weeks after initial vedolizumab (Entyvio) dose, notify ordering provider. 	
 Treatment for Adverse Drug Reactions (for mild to moderate infusion reaction) Slow or stop infusion for 20 minutes Give: • Diphenhydramine (Benadryl) - 25 mg IV Push, • Acetaminophen (Tylenol) - 650 mg, Oral. As needed for reactions. For pain/fever. If not already given as a "premedication". (Maximum Acetaminophen doses of 4000 mg in 24 hours from all combined sources.) • Methylprednisolone (Solu-Medrol) - 125 mg IV Push, if reaction continues • Place O2 PRN at 4 - 6 liters per nasal cannula STAT • Vital signs with PO2 every 5 minutes until stable • Notify the physician of reaction. Request further orders as indicated. • Complete adverse drug reaction PowerForm and document in the allergy profile for all drug reactions. 	
Provider Signature:	Date:
Provider Name and Credentials (please print):	Time:
Office Phone: Office Fax:	

Order is in effect for six (6) months following order date.

